Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment

NCT01530334 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Gefitinib 250mg

Sponsor

AstraZeneca